



**Global Harmonization Working Party**

GHWP Towards Medical Device Harmonization

# Progress of Medical Device Regulation in China

**Dong Jiangping**  
Director General of Department of Medical  
Device Regulation, NMPA China

# Contents

**Steady expansion of the industry scale**

**Continuous improvement of the regulatory system**

**Continuous manifestation of regulatory effect**

**Active engagement in international cooperation**


# Steady expansion of the industry scale



# The number of product registrations/filings has grown steadily

- From January to September 2024, a total of 12,944 various medical devices were approved for initial registration nationwide. Among them, 10371 domestic Class II medical devices and 2005 domestic Class III medical devices were approved for initial registration, respectively, and 568 imported medical devices (including Hong Kong, Macao, and Taiwan) were approved for initial registration.
- In the past five years, the registration/filing of medical devices in China has made great progress, especially the **annual compound growth rate of the number of Class II and III products for initial registration in China was 17.9% and 14.3%**, respectively, and mid-to-high-end products are increasingly favored by capital.

### Number of Medical Device Products Newly Registered/Filed in China from January 2018 to September 2024 (Unit: piece)




Data source: National Medical Products Administration



## The number of manufacturers has grown steadily

- In 2023, there were 32,300 medical device manufacturers in China, of which there were 3049 Class III medical device manufacturers, with an **increase of 21.5% year-on-year**.
- As of the end of September 2024, there were **32,700** medical device manufacturers.

**Trend of the total number of medical device manufacturers in China from January 2018 to September 2024 (Unit: 10,000 manufacturers)**



Note: An enterprises producing both Class I and Class III products is counted separately as manufacturer of Class I devices and Class III devices, and as one in the total number of enterprises.

Data source: National Medical Products Administration




**3**

## The number of distributors has increased rapidly

- In 2023, there were 1.3757 million Class II and III medical device distributors in China, with an **annual compound growth rate of 24.62%** from 2014 to 2023. The **rapid expansion of the medical device market, the need for professional services in medical institutions, and the expansion of the retail market** are the main drivers for the growth of distributors.
- As of the end of September 2024, there were **1.4154 million** Class II and III medical device distributors in China, and it is expected to reach 1.47 million for the whole year. The continuous expansion of the scale of medical device distributors has also promoted the vigorous development of the whole industry.

**Total number of medical device distributors in China from January 2018 to September 2024 (Unit: 10,000 distributors)**




Data source: National Medical Products Administration

## 4 The scale of revenue has grown steadily

- According to the estimate by the NMPA Southern Medicine Economic Research Institute, the business revenue of the whole medical device industry in China in 2023 was **1.31 trillion yuan**, with an annual compound growth rate of **10%** from 2014 to 2023, and the business revenue of manufacturers in China in 2024 was 1.35 trillion yuan, showing a slight increase compared with the previous year.


**Business revenue and forecast of medical device manufacturers in China from 2014 to 2024**



Data source: NMPA Southern Medicine Economic Research Institute

# Continuous improvement of the regulatory system





**The draft of the Medical Device Administration Law has been released for public comment**

**Regulations for the Supervision and Administration of Medical Devices (SC Decree No. 739 ), which came into force on June 1, 2021**

**14 department rules covering the full life cycle supervision including product registration, production, distribution, use, adverse event monitoring, recall, etc.**

**More than 140 normative documents**

**2017 medical device standards**  
**More than 600 technical guidelines related to registration, production and distribution**

# Continuous improvement of the regulatory system

## Adhering to open-door legislation



国家药品监督管理局  
National Medical Products Administration

无障碍 关怀版 中

请输入关键字

索引号	FGWJ-2024-10001	主题分类	法规文件 / 征求意见稿
标题	国家药监局综合司公开征求《中华人民共和国医疗器械管理法（草案征求意见稿）》意见		
发布日期	2024-08-28		

国家药监局综合司公开征求《中华人民共和国医疗器械管理法（草案征求意见稿）》意见

The NMPA has drafted the Medical Device Administration Law of the People's Republic of China (Draft for Comment), which was released for public comment on August 28. During the solicitation of comments, the NMPA organized representatives of enterprises, industry associations, experts and scholars, and regulatory representatives to hold special meetings on registration, production, distribution, use, online trading, import and export and other fields to listen to the opinions of all sectors of society.




# Continuous manifestation of regulatory effect

## Encouraging and supporting the development of innovative medical devices

- Guided by clinical needs, we have established a robust special review procedure for innovative medical devices, a priority approval procedure for medical devices, an emergency approval procedure for medical devices, and a conditional approval system for medical devices to speed up the marketing of innovative medical devices and medical devices in urgent clinical need.
- As of November 10, 2024, the NMPA has **approved 51 innovative medical devices**, an increase of 8.5% over the same period last year. **A total of 301 innovative medical devices have been approved.**

### Review and registration of innovative medical devices from 2014 to November 2024



Note: Data as of November 10, 2024

Data source: National Medical Products Administration, Center for Drug Evaluation

## Continuously promoting the improvement of standards

**A**

Coordinately promote the implementation of the new GB9706 series standards

**B**

Revise the classification catalogue for in vitro diagnostic reagents


**C**

Scientifically and dynamically adjust management categories

**D**

Organize the implementation of the third batch of UDIs

# Continuously strengthening the supervision of quality and safety throughout the life cycle





## Strengthening regulatory capacity building in an all-round way

- The construction of the review system has been comprehensively strengthened. As of the end of September 2024, there were 632 guidelines for the registration of medical devices in practice, and 1209 technical review points for medical devices formulated. The registration guidelines and technical review points have covered 96.1% of the Level 1 product categories in the Medical Device Classification Catalogue.
- The regulatory system and regulatory capacity continue to improve. There have been 265 national GCP inspectors and 546 national GMP inspectors. The inspector training and practical training have been well completed. A total of 8 medical device GMP inspector training sessions have been held in 2024, training a total of 9,317 national and provincial inspectors.

# Adhering to social co-governance

## Insist on the popularization of laws

Since 2020, the NMPA has continued to carry out publicity activities such as Medical Device Safety Promotion Week and National Drug Safety Promotion Week. By carrying out regulation publicity training, themed open day activities, discussions on supervision regulations, and publishing popular science works, we have comprehensively introduced medical device supervision regulation systems and common sense of safe use of devices to the society, enterprises and the public to ensure and promote public safety in the use of devices.



**全国医疗器械安全宣传周**  
MEDICAL DEVICE SAFETY PROMOTION WEEK

# Adhering to social co-governance

## Strengthen industry self-discipline

- Issue the Provisions for Supervision and Administration of Enterprises Implementing Responsibility as Entity of Medical Device Quality and Safety
- Give play to the role of relevant organizations such as the medical device industry associations
- Establish safety risk co-governance alliance for online sales



# Active engagement in international cooperation

## Active engagement in international cooperation



Actively participating in GHWP, Xu Jinghe, Deputy Commissioner of China's NMPA, was elected as the new president.

4 IMDRF clinical evaluation guidelines have been issued under the leadership of China's NMPA.

### **Actively participate in ISO and IEC activities.**

A total of 432 experts registering in international standards organizations have been dispatched to participate in the standard development and revision meetings of corresponding international organizations.





Thank You